Clinical Trial: Subconjunctival Bevacizumab and Recurrent Pterygium
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium
Brief Summary: A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.
Detailed Summary:
- Pacients with recurrent pterygium
- Anti-VEGF therapy -Bevacizumab
Sponsor: Instituto de Olhos de Goiania
Current Primary Outcome: Pterygium size after subconjunctival bevacizumab [ Time Frame: 8 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ]
Original Secondary Outcome: Same as current
Information By: Instituto de Olhos de Goiania
Dates:
Date Received: November 29, 2012
Date Started: February 2012
Date Completion:
Last Updated: December 6, 2012
Last Verified: December 2012